Laura Huppert, Md, Ba

This study tested if adding an immunotherapy drug (pembrolizumab) to a standard chemotherapy (carboplatin) could better control breast cancer that had returned to the chest wall. It involved 76 patients whose cancer had stopped responding to prior hormone therapies or was a type …